![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 56, Issue 1, 170-174, July 1999
Allergy Department, Schering-Plough Research Institute, Kenilworth,
New Jersey
The type 4 phosphodiesterase (PDE4) is the predominant PDE isozyme in
various leukocytes and plays a key role in the regulation of
inflammatory cell activation. There are four PDE4 subtypes (A, B, C,
and D), and within each subtype, there are multiple variants. Very
recently, we found in monocytes that PDE4B gene expression is
selectively induced by lipopolysaccharide (LPS) and that the induction
is inhibited by interleukin (IL)-10 and IL-4. In this study, we show
that the PDE4B gene is constitutively expressed in neutrophils and that
this expression remains unaffected by LPS or IL-10. PDE4B is the
predominant subtype in neutrophils and in unstimulated or
LPS-stimulated monocytes, and in these cells, the PDE4B2 variant is the
only detectable molecular species of PDE4B. Therefore, PDE4B2 is the
predominant PDE isoform in human neutrophils and monocytes, and its
expression is regulated differently by these two cell types.
Furthermore, leukocytes are the most dominant source of PDE4B2,
suggesting that PDE4B2 is a relatively specific target for discovering
anti-inflammatory drugs.
This article has been cited by other articles:
|
|
 |
|
  S.-W. Kim, D. Rai, M. R. McKeller, and R. C. T. Aguiar Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL Blood, June 11, 2009; 113(24): 6153 - 6160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Herve, T. Schmitz, D. Evain-Brion, D. Cabrol, M.-J. Leroy, and C. Mehats The PDE4 Inhibitor Rolipram Prevents NF-{kappa}B Binding Activity and Proinflammatory Cytokine Release in Human Chorionic Cells J. Immunol., August 1, 2008; 181(3): 2196 - 2202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Omori and J. Kotera Overview of PDEs and Their Regulation Circ. Res., February 16, 2007; 100(3): 309 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Schmitz, E. Souil, R. Herve, C. Nicco, F. Batteux, G. Germain, D. Cabrol, D. Evain-Brion, M.-J. Leroy, and C. Mehats PDE4 Inhibition Prevents Preterm Delivery Induced by an Intrauterine Inflammation J. Immunol., January 15, 2007; 178(2): 1115 - 1121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cheng and J. P. Grande Cyclic Nucleotide Phosphodiesterase (PDE) Inhibitors: Novel Therapeutic Agents for Progressive Renal Disease Experimental Biology and Medicine, January 1, 2007; 232(1): 38 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-F. Tang, Y.-H. Song, J.-C. Chen, J.-Q. Chen, and P. Wang Upregulation of Phosphodiesterase-4 in the Lung of Allergic Rats Am. J. Respir. Crit. Care Med., April 15, 2005; 171(8): 823 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ariga, B. Neitzert, S. Nakae, G. Mottin, C. Bertrand, M. P. Pruniaux, S.-L. C. Jin, and M. Conti Nonredundant Function of Phosphodiesterases 4D and 4B in Neutrophil Recruitment to the Site of Inflammation J. Immunol., December 15, 2004; 173(12): 7531 - 7538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Maresh, H. Xu, N. Jiang, and R. V. Shohet In Vivo Transcriptional Response of Cardiac Endothelium to Lipopolysaccharide Arterioscler. Thromb. Vasc. Biol., October 1, 2004; 24(10): 1836 - 1841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Barber, G. S. Baillie, R. Bergmann, M. C. Shepherd, R. Sepper, M. D. Houslay, and G. V. Heeke Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers Am J Physiol Lung Cell Mol Physiol, August 1, 2004; 287(2): L332 - L343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Oger, C. Mehats, M. S. Barnette, F. Ferre, D. Cabrol, and M.-J. Leroy Anti-Inflammatory and Utero-Relaxant Effects in Human Myometrium of New Generation Phosphodiesterase 4 Inhibitors Biol Reprod, February 1, 2004; 70(2): 458 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Heystek, A.-C. Thierry, P. Soulard, and C. Moulon Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity Int. Immunol., July 1, 2003; 15(7): 827 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Conti, W. Richter, C. Mehats, G. Livera, J.-Y. Park, and C. Jin Cyclic AMP-specific PDE4 Phosphodiesterases as Critical Components of Cyclic AMP Signaling J. Biol. Chem., February 14, 2003; 278(8): 5493 - 5496. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Oger, C. Mehats, E. Dallot, F. Ferre, and M.-J. Leroy Interleukin-1{beta} Induces Phosphodiesterase 4B2 Expression in Human Myometrial Cells through a Prostaglandin E2- and Cyclic Adenosine 3',5'-Monophosphate-Dependent Pathway J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5524 - 5531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-L. C. Jin and M. Conti Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses PNAS, May 28, 2002; 99(11): 7628 - 7633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Méhats, G. Tanguy, B. Paris, B. Robert, N. Pernin, F. Ferré, and M.-J. Leroy Pregnancy Induces a Modulation of the cAMP Phosphodiesterase 4-Conformers Ratio in Human Myometrium: Consequences for the Utero-Relaxant Effect of PDE4-Selective Inhibitors J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 817 - 823. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Sato, S. Sato, T. Yamamoto, S. Ishikawa, M. Onizuka, and Y. Sakakibara Phosphodiesterase type 4 inhibitor reduces the retention of polymorphonuclear leukocytes in the lung Am J Physiol Lung Cell Mol Physiol, June 1, 2002; 282(6): L1376 - L1381. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
